Drug Approval | March 12, 2022
China approves BeiGene’s tislelizumab
Tislelizumab is now approved for seven indications in China
Tislelizumab is now approved for seven indications in China
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Acute therapies continue to report strong growth compared to chronic ones.
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Subscribe To Our Newsletter & Stay Updated
